BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$58.51+0.52 (+0.90%)
Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –
BioMarin Pharmaceutical total assets
Total assets on the balance sheet at the end of each period.
BioMarin Pharmaceutical's total assets was $11.72B at Jun 30, 2026. For fiscal 2025 it was $7.59B, up 8.7% from the year before. Over ten years it grew 7.4% a year on average. The highest annual figure on record is $7.59B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.59B | +8.7% |
| FY2024 | Dec 31, 2024 | $6.99B | +2.2% |
| FY2023 | Dec 31, 2023 | $6.84B | +7.3% |
| FY2022 | Dec 31, 2022 | $6.38B | +6.2% |
| FY2021 | Dec 31, 2021 | $6.00B | +2.7% |
| FY2020 | Dec 31, 2020 | $5.85B | +24.7% |
| FY2019 | Dec 31, 2019 | $4.69B | +5.9% |
| FY2018 | Dec 31, 2018 | $4.43B | -4.4% |
| FY2017 | Dec 31, 2017 | $4.63B | +15.1% |
| FY2016 | Dec 31, 2016 | $4.02B | +7.9% |
| FY2015 | Dec 31, 2015 | $3.73B | +50.7% |
| FY2014 | Dec 31, 2014 | $2.48B | +10.3% |
| FY2013 | Dec 31, 2013 | $2.24B | +43.1% |
| FY2012 | Dec 31, 2012 | $1.57B | +20.1% |
| FY2011 | Dec 31, 2011 | $1.31B | +3.4% |
| FY2010 | Dec 31, 2010 | $1.26B | +37.7% |
| FY2009 | Dec 31, 2009 | $917.16M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.72B | +57.2% |
| Q1 FY2026 | Mar 31, 2026 | $8.59B | +20.2% |
| Q4 FY2025 | Dec 31, 2025 | $7.59B | +8.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.61B | +11.1% |
| Q2 FY2025 | Jun 30, 2025 | $7.46B | +5.5% |
| Q1 FY2025 | Mar 31, 2025 | $7.15B | +4.0% |
| Q4 FY2024 | Dec 31, 2024 | $6.99B | +2.2% |
| Q3 FY2024 | Sep 30, 2024 | $6.85B | +1.4% |
| Q2 FY2024 | Jun 30, 2024 | $7.07B | +7.7% |
| Q1 FY2024 | Mar 31, 2024 | $6.87B | +6.8% |
| Q4 FY2023 | Dec 31, 2023 | $6.84B | +7.3% |
| Q3 FY2023 | Sep 30, 2023 | $6.76B | +7.9% |
| Q2 FY2023 | Jun 30, 2023 | $6.56B | +6.8% |
| Q1 FY2023 | Mar 31, 2023 | $6.43B | +6.1% |
| Q4 FY2022 | Dec 31, 2022 | $6.38B | +6.2% |
| Q3 FY2022 | Sep 30, 2022 | $6.26B | +4.8% |
| Q2 FY2022 | Jun 30, 2022 | $6.15B | +4.2% |
| Q1 FY2022 | Mar 31, 2022 | $6.06B | +4.4% |
| Q4 FY2021 | Dec 31, 2021 | $6.00B | +2.7% |
| Q3 FY2021 | Sep 30, 2021 | $5.98B | -2.9% |
| Q2 FY2021 | Jun 30, 2021 | $5.90B | +11.2% |
| Q1 FY2021 | Mar 31, 2021 | $5.81B | +22.9% |
| Q4 FY2020 | Dec 31, 2020 | $5.85B | +24.7% |
| Q3 FY2020 | Sep 30, 2020 | $6.16B | +35.1% |
| Q2 FY2020 | Jun 30, 2020 | $5.30B | +20.7% |
| Q1 FY2020 | Mar 31, 2020 | $4.72B | +6.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.69B | +5.9% |
| Q3 FY2019 | Sep 30, 2019 | $4.56B | -2.9% |
| Q2 FY2019 | Jun 30, 2019 | $4.39B | -5.0% |
| Q1 FY2019 | Mar 31, 2019 | $4.44B | -3.5% |
| Q4 FY2018 | Dec 31, 2018 | $4.43B | -4.4% |
| Q3 FY2018 | Sep 30, 2018 | $4.70B | +2.5% |
| Q2 FY2018 | Jun 30, 2018 | $4.62B | +15.0% |
| Q1 FY2018 | Mar 31, 2018 | $4.60B | +16.7% |
| Q4 FY2017 | Dec 31, 2017 | $4.63B | +15.1% |
| Q3 FY2017 | Sep 30, 2017 | $4.58B | +19.2% |
| Q2 FY2017 | Jun 30, 2017 | $4.02B | – |
| Q1 FY2017 | Mar 31, 2017 | $3.94B | – |
| Q4 FY2016 | Dec 31, 2016 | $4.02B | – |
| Q3 FY2016 | Sep 30, 2016 | $3.84B | – |
See a number that looks wrong?